Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567671 · ClinicalTrials.gov registry record · Phase 2
Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia
A Phase 2 study of Corneal Ectasia and Progressive Keratoconus, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00567671: Completed Phase 2 study of Corneal Ectasia and Progressive Keratoconus, sponsored by Emory University.
NCT00567671 is a Phase 2 study of Corneal Ectasia and Progressive Keratoconus that has completed, run by Emory University. The registered enrollment target is 160 participants, below the 283-participant average among 3 other Corneal Ectasia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567671, a Phase 2 study of Corneal Ectasia and Progressive Keratoconus, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.
Conditions Studied
Interventions
- PROCEDURE Corneal collagen
- PROCEDURE Sham comparator
Study Locations (1)
Georgia
- Woolfson Eye Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00567671 record still lists
NCT00567671 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 3 other Corneal Ectasia trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Corneal Ectasia appearing as the primary indexed condition, and to 2 interventions - of which Corneal collagen is the first listed.
NCT00567671 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00567671 about?
NCT00567671 is a clinical study titled "Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia". Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.
What is the current status of trial NCT00567671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-12. Estimated completion is 2010-06.
What conditions does trial NCT00567671 study?
This clinical trial studies the following conditions: Corneal Ectasia, Progressive Keratoconus.
What interventions are being tested in trial NCT00567671?
The interventions under investigation include: Corneal collagen (PROCEDURE), Sham comparator (PROCEDURE).
Who is sponsoring clinical trial NCT00567671?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567671 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Ectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism
ACTIVE NOT RECRUITING · NA
-
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia